Eli Lilly today is the dominant player of the GLP-1 drug market.
It has a pair of GLP-1 products that make up more than half of its top line.
Competition in this space is growing, including from the best pharmaceutical companies.
10 shares we like more than Eli Lilly ›
Eli Lilly(NYS: LLY) There are the most valuable health care campaigns in the world with market capitalization of more than $ 760 billion. In recent years, it has been growing rapidly due to the very efficient GLP-1 products: Mounjaro for diabetes and weight loss.
However, whether it can continue higher collection and in the future to evaluate $ 1 trillion worth of dollars, it will probably depend on its GLP-1 products, as it has attracted many growth investors. However, many other companies have also aggressively directed to space to increase their sales and profits from the huge interest in weight loss medication.
One company recently announced its interest to be the best player in the GLP-1 market and could offer serious competition for Eli Lilly: Roche Holding (Otc: rhhby)
Image Source: Getty Images.
Roche, based in Switzerland, is an extraordinary Eli Lilly competitor because its market limit is about $ 300 billion, making it one of the largest companies in the sector. But one area where Roche behind is in the GLP-1 space.
However, this may change in the future when Pharma Company has recently announced that her injection medicine CT-388 is now starting stage 3 tests. CEO Teresa Graham says the company is seeking to be one of the leading GLP-1 players, noting that “we know how to break into new markets.” Roche has a rich growth history that is more than a century; The company was founded in 1896. Today, its portfolio is full of various drugs, and its bestseller is “Ocrevus”, the treatment of multiple sclerosis.
GLP-1 is a huge opportunity for Roche and CT-388 has shown positive benefits in an earlier study over the 24-week period, where participants have achieved an average placebo-adjusted weight loss of 18.8%. Clinical trials can take a lot of time, and even if the CT-388 is in the late stage, Roche is led that it can be started by 2030. He also works with other weight loss procedures, including the CT-996 pill, which is in previous stages.
Roche is just one example of rising competitions in the GLP-1 drug market. Pharmaceutical giant Pfizer recently announced plans to acquire Cities Because of its GLP-1 drug portfolio, hoping to keep up with. Previously, Pfizer has developed a weight loss pill that has been abandoned due to security issues. By purchasing it, she could quickly strengthen her portfolio and turn herself into a rival space.
There are many companies creating GLP-1 medicines, both large and small. Eli Lilly is in a great position, but already has an approved procedure in her portfolio and is good at introducing weight loss pills, perhaps next year. It has a great advantage over Roche, Pfizer and other companies that are still trying to get approved GLP-1 products in their portfolios.
During the first six months of the six years, Mounjar and Zepbound earned a $ 14.7 billion revenue for Eli Lilly, making more than half of its income.
Any fast -growing market will attract more companies and will cause intense competition, and the fight against default market is not an exception to this phenomenon. But Eli Lilly is an early leader and the ruthless pursuit of her innovation and more GLP-1 drug development is why I think everything will be fine and I think that in the next few years it should be the first health care company to estimate $ 1 trillion worth.
There will always be competition in the health care industry, but together with Eli Lilly investors receive a proven winner. Its shares have fallen by 4%in the last 12 months, and any slowdown can turn shares in an attractive opportunity to buy a long time. It currently sells 27 times the future earnings (based on analysts’ expectations), which is, of course, a purchase, taking into account its phenomenal growth potential.
Before buying Eli Lilly, consider this:
Motley Fool Stock Advisor A team of analysts just found what they think is 10 best stocks Investors to buy now … and Eli Lilly was not one of them. 10 stocks that reduced the incision can return the monster in the coming years.
Consider when Netflix This list consisted of 2004. December 17th … If you have invested $ 1,000 during our recommendation, at our recommendation, You would have $ 642 328!* Or when Nvidia Made this list in 2005. April 15 … If you have invested $ 1,000 during our recommendation, at our recommendation, You should have $ 1,134,270!*
Now it is worth mentioning Share advisor The average return is 1 064%-S&P 500, compared to 191%, market disorder. Don’t miss the latest top 10 lists that can be found with Share advisorand join the investment community that individual investors have built for individual investors.
See. 10 stocks »
*The stock advisor returns by 2025. October 7
David Jagielski has no position in any of the above shares. The Motley fool is a position and recommends Pfizer. Motley fool recommends Roche Holding AG. The Motley fool has a disclosure policy.
Beware of Eli Lilly, this pharmacy giant is forcing you to be the best player in the obesity market initially The Motley.
